Home › Gastrointestinal Cancers › Wisconsin
Gastrointestinal Cancers clinical trials in Wisconsin
7 studies for Gastrointestinal Cancers are looking for participants at sites in Wisconsin.
Cities in Wisconsin
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton, Appleton
- Duluth Clinic Ashland, Ashland
- and 29 more
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07283939Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study
- Marshfield Clinic-Chippewa Center, Chippewa Falls
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- and 1 more
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07215624A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UW Health Carbone Cancer Center, Madison
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06760819A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
- GSK Investigational Site, Milwaukee
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07218926Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06582017A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- University of Wisconsin- Madison, Madison
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
- GSK Investigational Site, Madison
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT06885034From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.